Market closedNon-fractional
Ovid Therapeutics/OVID
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Ovid Therapeutics
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
Ticker
OVID
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
New York, United States
Employees
40
Website
www.ovidrx.com
OVID Metrics
BasicAdvanced
$53M
Market cap
-
P/E ratio
-$0.72
EPS
0.69
Beta
-
Dividend rate
Price and volume
Market cap
$53M
Beta
0.69
Financial strength
Current ratio
10.465
Quick ratio
10.138
Long term debt to equity
18.434
Total debt to equity
20.054
Management effectiveness
Return on assets (TTM)
-28.10%
Return on equity (TTM)
-50.87%
Valuation
Price to revenue (TTM)
111.169
Price to book
0.67
Price to tangible book (TTM)
0.67
Price to free cash flow (TTM)
-1.043
Growth
Revenue change (TTM)
283.93%
Earnings per share change (TTM)
-1.38%
3-year revenue growth
-87.11%
3-year earnings per share growth
-26.12%
What the Analysts think about OVID
Analyst Ratings
Majority rating from 9 analysts.
OVID Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$100K
0.00%
Net income
-$12M
-24.18%
Profit margin
-11,600.00%
-24.18%
OVID Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.18
-$0.16
-$0.22
-$0.17
-
Expected
-$0.20
-$0.19
-$0.05
-$0.22
-$0.23
Surprise
-12.02%
-15.16%
342.53%
-21.97%
-
OVID News
AllArticlesVideos
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
Accesswire·1 day ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
PRNewsWire·4 days ago
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
GlobeNewsWire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ovid Therapeutics stock?
Ovid Therapeutics (OVID) has a market cap of $53M as of July 06, 2024.
What is the P/E ratio for Ovid Therapeutics stock?
The price to earnings (P/E) ratio for Ovid Therapeutics (OVID) stock is 0 as of July 06, 2024.
Does Ovid Therapeutics stock pay dividends?
No, Ovid Therapeutics (OVID) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Ovid Therapeutics dividend payment date?
Ovid Therapeutics (OVID) stock does not pay dividends to its shareholders.
What is the beta indicator for Ovid Therapeutics?
Ovid Therapeutics (OVID) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Ovid Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.